Clinical Trial Update: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial is evaluating Zanzalintinib versus Everolimus in locally advanced or metastatic neuroendocrine tumors, including pancreatic neuroendocri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapancreatic Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Everolimus (everolimus)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Exelixis | Conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | Phase 2, Phase 3 | Status: RECRUITING